Fmr LLC Acquires 267,842 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)

FMR LLC lifted its stake in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 9.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,053,126 shares of the company's stock after buying an additional 267,842 shares during the period. FMR LLC owned approximately 4.82% of Vera Therapeutics worth $129,117,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Huntington National Bank purchased a new position in Vera Therapeutics during the 4th quarter valued at about $26,000. AlphaQuest LLC bought a new stake in shares of Vera Therapeutics during the 4th quarter valued at $34,000. KBC Group NV grew its holdings in Vera Therapeutics by 127.2% in the fourth quarter. KBC Group NV now owns 2,477 shares of the company's stock worth $105,000 after purchasing an additional 1,387 shares during the period. Moors & Cabot Inc. bought a new position in Vera Therapeutics during the 4th quarter valued at approximately $220,000. Finally, E Fund Management Co. Ltd. raised its stake in Vera Therapeutics by 22.3% during the fourth quarter. E Fund Management Co. Ltd. now owns 6,203 shares of the company's stock valued at $262,000 after buying an additional 1,130 shares during the last quarter. 99.21% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

VERA has been the subject of several analyst reports. The Goldman Sachs Group assumed coverage on Vera Therapeutics in a report on Tuesday, January 28th. They set a "buy" rating and a $58.00 price target for the company. Guggenheim increased their price target on shares of Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a report on Thursday, February 27th. JPMorgan Chase & Co. decreased their price objective on shares of Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a report on Tuesday, March 4th. Finally, Wolfe Research initiated coverage on Vera Therapeutics in a report on Tuesday, February 4th. They set an "outperform" rating and a $49.00 price target on the stock. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $64.67.

Vera Therapeutics Stock Performance

Shares of NASDAQ:VERA traded up $0.05 during trading on Friday, hitting $21.29. The company's stock had a trading volume of 661,231 shares, compared to its average volume of 750,506. The company has a 50-day moving average of $26.35 and a 200-day moving average of $36.68. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. The firm has a market cap of $1.36 billion, a price-to-earnings ratio of -8.16 and a beta of 1.28. Vera Therapeutics, Inc. has a 12 month low of $18.53 and a 12 month high of $51.61.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.83) by $0.11. On average, sell-side analysts expect that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.